Endothelial function is impaired in HIV-infected patients with lipodystrophy

Carr A. , Samaras K. , Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–F58.

Grinspoon S. , Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48–62.

Coll B. , Parra S. , Alonso-Villaverde C. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine 2006; 34: 51–55.

Mercié P. , Thiébaut R. , Lavignolle V. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34: 55–63.

van Vonderen M.G. , Smulders Y.M. , Stehouwer C.D. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009; 50: 153–161.

Johnson J.A. , Albu J.B. , Engelson E.S. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286: E261–E271.

He G. , Andersen O. , Haugaard S.B. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest 2005; 35: 583–590.

Vigouroux C. , Maachi M. , Nguyen T.H. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17: 1503–1511.

Ross A.C. , Armentrout R. , Oriordan M.A. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008; 49: 499–506.

Saumoy M. , López-Dupla M. , Veloso S. The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes. AIDS 2008; 22: 893–896.

Lakka H.M. , Laaksonen D.E. , Lakka T.A. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.

Ford E.S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 307–314.

Calza L. , Manfredi R. , Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003; 22: 89–99.

Lichtenstein K.A. Redefining lipodystrophy syndrome. Risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39: 395–400.

Werns S.W. , Walton J.A. , Hsia H.H. , Nabel E.G. , Sanz M.L. , Pitt B. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989; 79: 287–291.

Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–809.

Ghiadoni L. , Versari D. , Giannarelli C. , Faita F. , Taddei S. Non-invasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des 2008; 14: 3715–3722.

Masiá M. , Bernal E. , Padilla S. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2007; 195: 167–171.

Juonala M. , Viikari J.S. , Laitinen T. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 2004; 110: 2918–2923.

Witte D.R. , Westerink J. , de Koning E.J. , van der Graaf Y. , Grobbee D.E. , Bots M.L. Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations? J Am Coll Cardiol 2005; 45: 1987–1993.

Odueyungbo A. , Smieja M. , Thabane L. Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study. AIDS Res Ther 2009; 6: 11.

Neunteuf T. , Katzenschlager R. , Hassan A. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111–118.

Chan S.Y. , Mancini G.B. , Kuramoto L. , Schulzer M. , Frohlich J. , Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003; 42: 1037–1043.

Wassmann S. , Stumpf M. , Strehlow K. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94: 534–541.

Ikeda U. , Ikeda M. , Oohara T. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol 1991; 260: H1713–H1717.

Senn J.J. , Klover P.J. , Nowak I.A. , Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391–3399.

Kim J.A. , Montagnani M. , Koh K.K. , Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888–1904.

Muniyappa R. , Quon M.J. Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 2007; 10: 523–530.

Lihn A.S. , Richelsen B. , Pedersen S.B. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003; 285: E1072–E1080.

Ouchi N. , Kihara S. , Arita Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296–1301.

Ouchi N. , Kihara S. , Arita Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473–2476.

Chudek J. , Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006; 58 Suppl: 81–88.

Eschen O. , Christensen J.H. , Dethlefsen C. , Schmidt E.B. Cellular adhesion molecules in healthy subjects: short term variations and relations to flow mediated dilation. Biomark Insights 2008; 3: 57–62.

Głowińska-Olszewska B. , Tołwińska J. , Urban M. Relationship between endothelial dysfunction, carotid artery intima media thickness and circulating markers of vascular inflammation in obese hypertensive children and adolescents. J Pediatr Endocrinol Metab 2007; 20: 1125–1136.

Blankenberg S. , Barbaux S. , Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191–203.

Kohler H.P. , Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–1801.

Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30: 13–19.

Hadigan C. , Meigs J.B. , Rabe J. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86: 939–943.

Mulligan K. , Parker R.A. , Komarow L. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006; 41: 590–597.

Tien P.C. , Cole S.R. , Williams C.M. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003; 34: 461–466.

Bacchetti P. , Gripshover B. , Grunfeld C. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40: 121–131.

Yan R.T. , Anderson T.J. , Charbonneau F. , Title L. , Verma S. , Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005; 45: 1980–1986.

Philpott A.C. , Lonn E. , Title L.M. Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors. Am J Cardiol 2009; 103: 1610–1615.

Solages A. , Vita J.A. , Thornton D.J. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42: 1325–1332.

Francisci D. , Giannini S. , Baldelli F. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009; 23: 589–596.

Mu H. , Chai H. , Lin P.H. , Yao Q. , Chen C. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007; 31: 632–643.

Andrade A.C. , Ladeia A.M. , Netto E.M. Cross-sectional study of endothelial function in HIV-infected patients in Brazil. AIDS Res Hum Retroviruses 2008; 24: 27–33.

Stein J.H. , Klein M.A. , Bellehumeur J.L. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257–262.

Hsue P.Y. , Hunt P.W. , Wu Y. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23: 2021–2027.

Torriani F.J. , Komarow L. , Parker R.A. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52: 569–576.